July 30, 2026

#diabetes — Thursday, July 30, 2026 (3 items)

hot top new

ℹ	Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. (linkinghub.elsevier.com)	Mora P … Rosenstock J The Lancet 2026-07-30	#diabetes #clinical trial #pharmacology #therapeutics
ℹ	Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes. (nature.com)	Liu PY … Sung JM Nature Communications 2026-07-30	#cardiovascular #heart failure #diabetes #nephrology #pharmacoepidemiology
ℹ	Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. (linkinghub.elsevier.com)	Mora P … Rosenstock J The Lancet 2026-07-30	#diabetes #clinical trial #pharmacology #therapeutics